相关实验视频
Updated: Jun 16, 2025

09:39
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
9.4K
在IBD患者中,JAK抑制剂和癌症风险
Francesca Bernardi1,2, Ilaria Faggiani1,2, Tommaso Lorenzo Parigi1
1Gastroenterology and Endoscopy IRCCS, Ospedale San Raffaele, Via Olgettina 60, 20132 Milano, Italy.
Cancers
|June 13, 2025
概括
简氏激酶 (JAK) 抑制剂对炎症性肠道疾病 (IBD) 有效. 长期数据显示,这些JAK抑制剂不会增加IBD患者的恶性瘤风险,支持它们的持续使用.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 简氏激酶 (JAK) 抑制剂越来越多地用于炎症性肠道疾病 (IBD).
- 这些药物向JAK-STAT通路,对免疫反应和炎症至关重要.
- 有关潜在的恶性瘤风险存在担忧,正如风湿性关节炎研究所显示的那样.
研究的目的:
- 评估JAK抑制剂治疗与IBD患者相关的瘤风险.
- 评估JAK抑制剂对IBD患者恶性瘤发展的长期安全性.
主要方法:
- 观察性研究和临床试验数据的审查.
- 对接受JAK抑制剂治疗的IBD患者的长期随访数据 (长达10年) 的分析.
- 与一般人口或安慰剂组 (隐含) 相比,对IBD患者恶性瘤发病率的评估.
主要成果:
- 目前的证据并不表明使用JAK抑制剂的IBD患者患上瘤发生的风险增加.
- 长期随访数据高达10年,对恶性瘤的风险令人放心.
- 在类风湿性关节炎患者中观察到的可变风险表明,JAK抑制剂的选择性可能会影响结果.
结论:
- 在IBD患者的恶性瘤风险方面,JAK抑制剂治疗通常是安全的.
- 持续警,患者分层和量身定制的监测对于管理潜在的不良影响至关重要.
- 令人放心的长期安全数据支持在适当的临床环境中继续使用JAK抑制剂来治疗IBD.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160

